Mumbai: The Department of Atomic Energy (DAE) in collaboration with IDRS Labs on Wednesday launched 'ActoCyte', a food supplement or nutraceutical that aims to enhance the quality of life of cancer patients undergoing radiotherapy.
AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI), an official release said.
Scientists at Bhabha Atomic Research Centre, Mumbai; Advanced Center for Training Research and Education in Cancer, Navi Mumbai, Tata Memorial Hospital, Mumbai; And officials of M/s IDRS Labs, involved in the manufacturing of the tablet, were present during the launch event.
TMC Director Dr. Sudeep Gupta said that the first step towards the development of this tablet was taken about 25 years ago.
Doctors at TMC said AKTOCYTE tablets have shown remarkable results, especially in pelvic cancer patients suffering from radiotherapy-induced side effects. They said patients treated with AKTOCYTE tablets demonstrated extraordinary recovery from radiotherapy-mediated toxicities.
Designed as an adjunct to cancer radiotherapy, regenerative nutraceutical, immunomodulator and antioxidant, the tablet marks a significant advancement in cancer care, he said, emphasizing that it is not a substitute for any existing cancer treatment.
Dr. Gupta said that AKTOCYTE has received approval from FSSAI as a nutraceutical, and necessary studies are required to establish whether it can also be used as a medicine for a specific purpose.
AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI), an official release said.
Scientists at Bhabha Atomic Research Centre, Mumbai; Advanced Center for Training Research and Education in Cancer, Navi Mumbai, Tata Memorial Hospital, Mumbai; And officials of M/s IDRS Labs, involved in the manufacturing of the tablet, were present during the launch event.
TMC Director Dr. Sudeep Gupta said that the first step towards the development of this tablet was taken about 25 years ago.
Doctors at TMC said AKTOCYTE tablets have shown remarkable results, especially in pelvic cancer patients suffering from radiotherapy-induced side effects. They said patients treated with AKTOCYTE tablets demonstrated extraordinary recovery from radiotherapy-mediated toxicities.
Designed as an adjunct to cancer radiotherapy, regenerative nutraceutical, immunomodulator and antioxidant, the tablet marks a significant advancement in cancer care, he said, emphasizing that it is not a substitute for any existing cancer treatment.
Dr. Gupta said that AKTOCYTE has received approval from FSSAI as a nutraceutical, and necessary studies are required to establish whether it can also be used as a medicine for a specific purpose.
